Please provide your email address to receive an email when new articles are posted on . Approximately 48% of patients underwent a follow-up colonoscopy within 6 months of abnormal stool-based ...

The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release. Compared ...

An investigational multitarget stool DNA test for screening colorectal cancer detects significantly more cancers than the currently available fecal immunochemical test (FIT), researchers report. But ...

When given a choice, most individuals with an average risk of colorectal cancer said they would prefer a stool-based screening test for colorectal cancer over colonoscopy, the method most often ...

A stool test is a diagnostic procedure that involves analyzing fecal matter, or poop, to check for signs of infection, inflammation, or disease. The specific analysis depends on a person’s symptoms ...

Colorectal cancer is one of the leading causes of cancer deaths worldwide. Until now, colonoscopy has been the most reliable test, but many people avoid it because it is invasive, expensive, and ...

A next-generation multitarget stool DNA test, including assessments of DNA molecular markers and hemoglobin level, was developed to improve the performance of colorectal cancer screening, primarily ...

Kentucky has one of the highest rates of colorectal cancer in the US, but early detection leads to a 91% five-year survival rate. Colorectal cancer is projected to become the leading cancer killer for ...

In average-risk individuals, ColoSense demonstrated 93% sensitivity for detecting colorectal cancer (CRC) and 45% sensitivity for detecting advanced adenomas (AA). The CRC-PREVENT study evaluated more ...

Kentucky has long carried one of the highest burdens of colorectal cancer in the nation. For too many families, it is a diagnosis that comes too late and with too few effective treatment options. But ...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug ...